Allergic Rhinitis Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, P

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Allergic Rhinitis pipeline constitutes 35+ key companies continuously working towards developing 35+ Allergic Rhinitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Allergic Rhinitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Allergic Rhinitis Market.

The Allergic Rhinitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Allergic Rhinitis Pipeline Report: https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Allergic Rhinitis treatment therapies with a considerable amount of success over the years.
• Allergic Rhinitis companies working in the treatment market are Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, Qyuns Therapeutics, Worg Pharmaceuticals, Altamira Therapeutics, DC4U, Desentum, Funpep, and others, are developing therapies for the Allergic Rhinitis treatment
• Emerging Allergic Rhinitis therapies in the different phases of clinical trials are- EGN1908-1909, IRL201104, PA9159, AI201901, REGN 5713 5714 5715, CSPCHA115, MM09, CEN501, MG 01/T 517, Grass MATA MPL, REVTx-99b, ILT-101, AD17002, B244, DW2008, INI-2004, STMC-103H, BM41, HY-083, QX 005N, FPP004, and others are expected to have a significant impact on the Allergic Rhinitis market in the coming years.
• In November 2022, Hyloris Pharmaceuticals SA has introduced a novel proprietary formulation, specifically a TRPV1 agonist, administered through intranasal spray for the treatment of idiopathic rhinitis. Idiopathic rhinitis is characterized by an excessive expression of TRPV1 in the nasal mucosa, leading to symptoms such as nasal obstruction, rhinorrhea (commonly known as a runny nose), and/or sneezing.
• In June 2022, Revelation Biosciences Inc. has successfully concluded the enrollment and dosing phase of its Phase Ib CLEAR clinical trial, evaluating the safety and effectiveness of intranasal REVTx-99b in treating allergic rhinitis. REVTx-99b is a proprietary intranasal formulation designed to address allergic rhinitis symptoms, including persistent nasal congestion. In a Phase I clinical study, the active ingredient demonstrated the ability to upregulate a protein that competes with the native eotaxin receptor, CCR3. This process helps prevent the recruitment of eosinophils and basophils by eotaxin, ultimately reducing Th2 cell recruitment and mitigating the allergic response.
• In May 2022, ABVC Biopharma, Inc. has reported that its wholly-owned subsidiary, BioKey, located in Fremont, California, has secured a clinical services contract worth $3.0 million with NeuCen BioMed Co. Ltd. The contract involves guiding two NeuCen drug products, CEN501 and NEU001, through the Phase II clinical studies in accordance with the regulatory requirements of the US FDA IND. CEN501 is a nasal strip product utilized as a local nasal immunotherapy (LNIT) for treating allergic rhinitis induced by mites. The effectiveness and safety of CEN501 have been successfully demonstrated in two preliminary clinical trials conducted in Taiwan.
• Inimmune is in the process of creating a swift, disease-modifying treatment that eliminates the need for allergen identification. INI-2004, an allergen-agnostic immunotherapy, engages Toll-like receptor 4. Administered intranasally, INI-2004 significantly diminished indicators of allergic rhinitis (AR) in pre-clinical animal models. These indicators encompassed reduced airway resistance, decreased eosinophil influx, and a decline in the production of cytokines associated with allergic responses. The commencement of Phase I clinical studies is scheduled for Q2 2023.

Allergic Rhinitis Overview
Allergic rhinitis, commonly known as hay fever, is an inflammatory condition of the nasal passages caused by an allergic reaction to airborne allergens. These allergens can include pollen, mold spores, dust mites, animal dander, and certain air pollutants. When individuals with allergic rhinitis come into contact with these triggers, their immune system releases chemicals, such as histamines, leading to symptoms.

Get a Free Sample PDF Report to know more about Allergic Rhinitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/allergic-rhinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Allergic Rhinitis Drugs Under Different Phases of Clinical Development Include:
• FPP004: Funpep
• INI 2004: Inimmune
• TQC 3564: Chia Tai Tianqing Pharmaceutical Group
• ILT-101: Iltoo Pharma
• IRL201104: Revolo Biotherapeutics
• PA9159: Anhui Palo Alto Pharmaceuticals
• MM09-MG01: Immunotek SL
• AI201901: Abdi Ibrahim Pharmaceuticals
• REGN1908-1909: Regeneron
• Glycopyranosyl lipid adjuvant: Revelation Biosciences
• QX 005N: Qyuns Therapeutics
• HY-083: Hyloris Pharmaceuticals

Allergic Rhinitis Route of Administration
Allergic Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Allergic Rhinitis Molecule Type
Allergic Rhinitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Allergic Rhinitis Pipeline Therapeutics Assessment
• Allergic Rhinitis Assessment by Product Type
• Allergic Rhinitis By Stage and Product Type
• Allergic Rhinitis Assessment by Route of Administration
• Allergic Rhinitis By Stage and Route of Administration
• Allergic Rhinitis Assessment by Molecule Type
• Allergic Rhinitis by Stage and Molecule Type

DelveInsight's Allergic Rhinitis Report covers around 35+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Allergic Rhinitis product details are provided in the report. Download the Allergic Rhinitis pipeline report to learn more about the emerging Allergic Rhinitis therapies at:
https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Allergic Rhinitis Therapeutics Market include:
Key companies developing therapies for Allergic Rhinitis are - Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, and others.

Allergic Rhinitis Pipeline Analysis:
The Allergic Rhinitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Allergic Rhinitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Allergic Rhinitis Treatment.
• Allergic Rhinitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Allergic Rhinitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Allergic Rhinitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Allergic Rhinitis drugs and therapies-
https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Allergic Rhinitis Pipeline Market Drivers
• Increase in the prevalence of various form of allergic rhinitis, surge in the demand for effective and potent drugs among consumers across the globe are some of the important factors that are fueling the Allergic Rhinitis Market.

Allergic Rhinitis Pipeline Market Barriers
• However, high competition from generic drugs, side-effects associated with the allergic rhinitis treatment and other factors are creating obstacles in the Allergic Rhinitis Market growth.

Scope of Allergic Rhinitis Pipeline Drug Insight
• Coverage: Global
• Key Allergic Rhinitis Companies: Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, Qyuns Therapeutics, Worg Pharmaceuticals, Altamira Therapeutics, DC4U, Desentum, Funpep, and others
• Key Allergic Rhinitis Therapies: EGN1908-1909, IRL201104, PA9159, AI201901, REGN 5713 5714 5715, CSPCHA115, MM09, CEN501, MG 01/T 517, Grass MATA MPL, REVTx-99b, ILT-101, AD17002, B244, DW2008, INI-2004, STMC-103H, BM41, HY-083, QX 005N, FPP004, and others
• Allergic Rhinitis Therapeutic Assessment: Allergic Rhinitis current marketed and Allergic Rhinitis emerging therapies
• Allergic Rhinitis Market Dynamics: Allergic Rhinitis market drivers and Allergic Rhinitis market barriers

Request for Sample PDF Report for Allergic Rhinitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Allergic Rhinitis Report Introduction
2. Allergic Rhinitis Executive Summary
3. Allergic Rhinitis Overview
4. Allergic Rhinitis- Analytical Perspective In-depth Commercial Assessment
5. Allergic Rhinitis Pipeline Therapeutics
6. Allergic Rhinitis Late Stage Products (Phase II/III)
7. Allergic Rhinitis Mid Stage Products (Phase II)
8. Allergic Rhinitis Early Stage Products (Phase I)
9. Allergic Rhinitis Preclinical Stage Products
10. Allergic Rhinitis Therapeutics Assessment
11. Allergic Rhinitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Allergic Rhinitis Key Companies
14. Allergic Rhinitis Key Products
15. Allergic Rhinitis Unmet Needs
16 . Allergic Rhinitis Market Drivers and Barriers
17. Allergic Rhinitis Future Perspectives and Conclusion
18. Allergic Rhinitis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Allergic Rhinitis Market https://www.delveinsight.com/report-store/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Allergic Rhinitis Epidemiology https://www.delveinsight.com/report-store/allergic-rhinitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Allergic Rhinitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.